|
Vertex, CRO Miscommunication Causes Backpedaling on CF Data
Vertex’s cystic fibrosis (CF) program took a hit May 29 when the company announced it had mischaracterized data from an interim analysis of an ongoing Phase II study of Kalydeco and investigational drug VX-809.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives